Early stent thrombosis with bivalirudin in patients undergoing percutaneous coronary intervention

Summary

Although bivalirudin has been shown to reduce bleeding events in patients undergoing percutaneous coronary intervention, residual concerns remain about a possible higher risk of early (within 30 days) stent thrombosis (ST). Therefore, we performed a meta-analysis of randomised trials reporting ST events with bivalirudin compared to other antithrombotic therapies (heparins ± glycoprotein IIb/IIIa inhibitors). A systematic literature search of electronic resources was performed through May, 2014. The primary endpoint was definite early ST, according to Academic Research Consortium criteria. Secondary endpoints included: all-cause death, myocardial infarction and major bleeding. A total of 11 trials, including 16,415 patients, were accrued. Compared to other regimens, bivalirudin significantly increased the risk of early ST (odds ratio [OR]=1.80; 95 % confidence interval [CI], 1.28 2.52; p=0.0007) and reduced the risk of major bleeding (OR [95 %CI]=0.64 [0.51 0.82], p=0.0003), with a comparable risk of mortality or myocardial infarction. The higher risk of early ST was mainly attributable to acute (OR [95 % CI] =4.33 [2.33 8.05], p < 0.001) than subacute (OR [95 % CI] =0.89 [0.53 1.50], p =0.67) ST events (p for interaction < 0.001). Non-fatal myocardial infarction was the most common presentation (83 %) of early ST events, while death occurred infrequently (about 5 %). In conclusion, in patients undergoing PCI, bivalirudin compared to heparins is associated with a higher risk of early ST, which is mainly related to more frequent acute events. Further studies are required to evaluate alternative strategies to mitigate this risk, without hampering the benefits derived from the reduction in bleeding events with bivalirudin.

Keywords

Bivalirudin - stent thrombosis - major bleeding - percutaneous coronary intervention - myocardial infarction

• References

• 1 Hirsh J, O’Donnell M, Eikelboom JW. Beyond unfractionated heparin and warfarin: current and future advances. Circulation 2007; 116: 552-560.
• 2 Rao SV, Ohman EM. Anticoagulant therapy for percutaneous coronary intervention. Circ Cardiovasc Interv 2010; 03: 80-88.
• 3 Warkentin TE, Greinacher A, Koster A. Bivalirudin. Thromb Haemost 2008; 99: 830-839.
• 4 Coppens M, Eikelboom JW, Gustafsson D. et al. Translational success stories: development of direct thrombin inhibitors. Circ Res 2012; 111: 920-929.
• 5 De Luca G, Cassetti E, Verdoia M. et al. Bivalirudin as compared to unfractionated heparin among patients undergoing coronary angioplasty: A meta-analyis of randomised trials. Thromb Haemost 2009; 102: 428-436.
• 6 Cook S, Windecker S. Early stent thrombosis: past, present, and future. Circulation 2009; 119: 657-659.
• 7 Holmes DR Jr., Kereiakes DJ, Garg S. et al. Stent thrombosis. J Am Coll Cardiol 2010; 56: 1357-1365.
• 8 Mehta SR. Balancing thrombotic events and bleeding in primary PCI. N Engl J Med 2013; 369: 2263-2265.
• 9 Cutlip DE, Windecker S, Mehran R. et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007; 115: 2344-2351.
• 10 Harbord RM, Egger M, Sterne JA. A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Stat Med 2006; 25: 3443-3457.
• 11 Peters JL, Sutton AJ, Jones DR. et al. Comparison of two methods to detect publication bias in meta-analysis. J Am Med Assoc 2006; 295: 676-680.
• 12 Piccolo R, Galasso G, Capuano E. et al. Transradial versus Transfemoral Approach in Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndrome. A Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Trials. PLoS One 2014; 09: e96127.
• 13 Wetterslev J, Thorlund K, Brok J. et al. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. J Clin Epidemiol 2008; 61: 64-75.
• 14 Moher D, Liberati A, Tetzlaff J. et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Br Med J 2009; 339: b2535.
• 15 Patti G, Pasceri V, D’Antonio L. et al. Comparison of safety and efficacy of bivalirudin versus unfractionated heparin in high-risk patients undergoing percutaneous coronary intervention (from the Anti-Thrombotic Strategy for Reduction of Myocardial Damage During Angioplasty-Bivalirudin vs Heparin study). Am J Cardiol 2012; 110: 478-484.
• 16 Parodi G, Migliorini A, Valenti R. et al. Comparison of bivalirudin and unfractionated heparin plus protamine in patients with coronary heart disease undergoing percutaneous coronary intervention (from the Antithrombotic Regimens aNd Outcome [ARNO] trial). Am J Cardiol 2010; 105: 1053-1059.
• 17 Schulz S, Richardt G, Laugwitz KL. et al. Prasugrel plus bivalirudin vs clopidogrel plus heparin in patients with ST-segment elevation myocardial infarction. Eur Heart J 2014; 35: 2285-2294.
• 18 Steg PG, van ’t Hof A, Hamm CW. et al. Bivalirudin started during emergency transport for primary PCI. N Engl J Med 2013; 369: 2207-2217.
• 19 Shahzad A, Kemp I, Mars C. et al. Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial. Lancet. 2014. Epub ahead of print.
• 20 Stone GW, Witzenbichler B, Guagliumi G. et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008; 358: 2218-2230.
• 21 Kastrati A, Neumann FJ, Mehilli J. et al. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention. N Engl J Med 2008; 359: 688-696.
• 22 Kastrati A, Neumann FJ, Schulz S. et al. Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction. N Engl J Med 2011; 365: 1980-1989.
• 23 Tavano D, Visconti G, D’Andrea D. et al. Comparison of bivalirudin monotherapy versus unfractionated heparin plus tirofiban in patients with diabetes mellitus undergoing elective percutaneous coronary intervention. Am J Cardiol 2009; 104: 1222-1228.
• 24 Briguori C. Novel Approaches in Preventing or Limiting Event (NAPLES) III Trial. Presented at the American College of Cardiology Scientific Session Washington, DC, March 29, 2014 Available at http://www.cardiosource.org/~/media/Files/Science and Quality/Clinical Trials/ACC 14 Slides/NAPLES III ACC14 Presentation Slides.ashx
• 25 Waksman R, Bertrand O, Driesman M. et al. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention in patients with non-STsegment elevation acute coronary syndrome initially treated with fondaparinux: results from an international multicenter, randomized pilot study (SWITCH III). J Interv Cardiol 2013; 26: 107-113.
• 26 Doyle BJ, Rihal CS, Gastineau DA. et al. Bleeding, blood transfusion and increased mortality after percutaneous coronary intervention: implications for contemporary practice. J Am Coll Cardiol 2009; 53: 2019-2027.
• 27 Eikelboom JW, Mehta SR, Anand SS. et al. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 2006; 114: 774-782.
• 28 Chatterjee S, Wetterslev J, Sharma A. et al. Association of blood transfusion with increased mortality in myocardial infarction: a meta-analysis and diversity-adjusted study sequential analysis. J Am Med Assoc Intern Med 2013; 173: 132-139.
• 29 Hamon M, Nienaber CA, Galli S. et al. Bivalirudin in percutaneous coronary intervention: The EUROpean BiValIrudin UtiliSatION in Practice (EUROVISION) Registry. Int J Cardiol 2014; 173: 290-294.
• 30 Shelton R, Eftychiou C, Somers K. et al. Bivalirudin in patients undergoing primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: outcomes in a large real-world population. EuroInterv 2013; 09: 118-124.
• 31 van Werkum JW, Heestermans AA, Zomer AC. et al. Predictors of coronary stent thrombosis: the Dutch Stent Thrombosis Registry. J Am Coll Cardiol 2009; 53: 1399-1409.
• 32 Dangas GD, Claessen BE, Mehran R. et al. Clinical outcomes following stent thrombosis occurring in-hospital versus out-of-hospital: results from the HORIZONS-AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) trial. J Am Coll Cardiol 2012; 59: 1752-1759.
• 33 Dangas GD, Mehran R, Nikolsky E. et al. Effect of switching antithrombin agents for primary angioplasty in acute myocardial infarction: the HORIZONSSWITCH analysis. J Am Coll Cardiol 2011; 57: 2309-2316.
• 34 Koutouzis M, Lagerqvist B, James S. et al. Unfractionated heparin administration in patients treated with bivalirudin during primary percutaneous coronary intervention is associated lower mortality and target lesion thrombosis: a report from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Heart 2011; 97: 1484-1488.
• 35 Cavender MA, Sabatine MS. Bivalirudin versus heparin in patients planned for percutaneous coronary intervention: a meta-analysis of randomised controlled trials. Lancet 2014; 384: 599-606.
• 36 Clemmensen P, van’t Hof A, Deliargyris E. et al. Predictors associated with acute stent thrombosis after primary PCI: The EUROMAX trial. J Am Coll Cardiol 2014; 63: A27.
• 37 Alexopoulos D, Xanthopoulou I, Gkizas V. et al. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction. Circ Cardiovasc Interv 2012; 05: 797-804.
• 38 Piccolo R, Di Gioia G, Niglio T. et al. Pharmacotherapeutic considerations for the use of prasugrel and ticagrelor to reduce stent thrombosis in patients with acute coronary syndrome. Angiology 2014; 65: 130-136.
• 39 Urban P, Abizaid A, Banning A. et al. Stent thrombosis and bleeding complications after implantation of sirolimus-eluting coronary stents in an unselected worldwide population: a report from the e-SELECT (Multi-Center Post-Market Surveillance) registry. J Am Coll Cardiol 2011; 57: 1445-1454.
• 40 Tarantini G, Brener SJ, Barioli A. et al. Impact of baseline hemorrhagic risk on the benefit of bivalirudin versus unfractionated heparin in patients treated with coronary angioplasty: a meta-regression analysis of randomized trials. Am Heart J 2014; 167: 401-412 e406.